MDM2 SNP309 contributes to tumor susceptibility： A meta-analysis

The potentially functional polymorphism, SNP309, in the promoter region of MDM2 gene has been implicated in cancer risk, but individual published studies showed inconclusive results. To obtain a more precise estimate of the association between MDM2 SNP309 and risk of cancer, we performed a meta-anal...

Full description

Saved in:
Bibliographic Details
Published inJournal of genetics and genomics Vol. 38; no. 8; pp. 341 - 350
Main Authors Wo, Xiaoman, Han, Dong, Sun, Haiming, Liu, Yang, Meng, Xiangning, Bai, Jing, Chen, Feng, Yu, Yang, Jin, Yan, Fu, Songbin
Format Journal Article
LanguageEnglish
Published China Elsevier Ltd 20.08.2011
Subjects
Biomarkers, Tumor - genetics
Cancer risk
Genetic Predisposition to Disease
Genotype
Humans
MDM2
Meta-analysis
Neoplasms - genetics
Polymorphism
Polymorphism, Single Nucleotide
Promoter Regions, Genetic - genetics
Proto-Oncogene Proteins c-mdm2 - genetics
Risk Factors
可信区间
易感性
潜在功能
生物标志物
肿瘤
遗传模型
随机效应模型
MDM2
Polymorphism
Cancer risk
Meta-analysis
Online AccessGet full text

Cover

More Information
Summary:The potentially functional polymorphism, SNP309, in the promoter region of MDM2 gene has been implicated in cancer risk, but individual published studies showed inconclusive results. To obtain a more precise estimate of the association between MDM2 SNP309 and risk of cancer, we performed a meta-analysis of 70 individual studies in 59 publications that included 26,160 cases with different types of tumors and 33,046 controls. Summary odds ratios （OR） and corresponding 95% confidence intervals （CIs） were estimated using fixed- and random-effects models when appropriate. Overall, the variant genotypes were associated with a significantly increased cancer risk for all cancer types in different genetic models （GG vs. TT： OR, 1.123; 95% CI, 1.056--1.193; GG/GT vs. TT： OR, 1.028; 95% CI, 1.006--1.050）. In the stratified analyses, the increased risk remained for the studies of most types of cancers, Asian populations, and hospital-/population-based studies in different genetic models, whereas significantly decreased risk was found in prostate cancer （GG vs. TT： OR, 0.606; 95% CI, 0.407-0.903; GG/GT vs. TT： OR, 0.748; 95% CI, 0.579--0.968）. In conclusion, the data of meta-analysis suggests that MDM2 SNP309 is a potential biomarker for cancer risk.
Bibliography:The potentially functional polymorphism, SNP309, in the promoter region of MDM2 gene has been implicated in cancer risk, but individual published studies showed inconclusive results. To obtain a more precise estimate of the association between MDM2 SNP309 and risk of cancer, we performed a meta-analysis of 70 individual studies in 59 publications that included 26,160 cases with different types of tumors and 33,046 controls. Summary odds ratios （OR） and corresponding 95% confidence intervals （CIs） were estimated using fixed- and random-effects models when appropriate. Overall, the variant genotypes were associated with a significantly increased cancer risk for all cancer types in different genetic models （GG vs. TT： OR, 1.123; 95% CI, 1.056--1.193; GG/GT vs. TT： OR, 1.028; 95% CI, 1.006--1.050）. In the stratified analyses, the increased risk remained for the studies of most types of cancers, Asian populations, and hospital-/population-based studies in different genetic models, whereas significantly decreased risk was found in prostate cancer （GG vs. TT： OR, 0.606; 95% CI, 0.407-0.903; GG/GT vs. TT： OR, 0.748; 95% CI, 0.579--0.968）. In conclusion, the data of meta-analysis suggests that MDM2 SNP309 is a potential biomarker for cancer risk.
MDM2; Polymorphism; Cancer risk; Meta-analysis
11-5450/R
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ISSN:1673-8527
DOI:10.1016/j.jgg.2011.07.005